Advances in blood cancer patient monitoring: Why MRD should be part of the conversation

Please join us for educational programs and interactive discussions with renowned physicians to discuss the utility of minimal residual disease (MRD) assessment in blood cancers.

Hosted by Adaptive biotechnologies®

A series of live, one-hour webinar events that include participant polling and Q&A sessions with the experts.

Chronic Lymphocytic Leukemia (CLL)

John Pagel, MD, PhD
Chief of Hematologic Malignancies, Director of Hematopoietic Stem Cell Transplantation Program, Swedish Cancer Institute Seattle, WA

Dr. Pagel’s research interests include the development and discovery of novel therapeutics for the treatment of blood cancers, including lymphoma and leukemia. His current research focuses on strategies for delivering innovative targeted immunotherapy agents to patients with hematologic malignancies. His research has resulted in over 100 publications in peer-reviewed journals, including, but not limited to, the New England Journal of Medicine, Blood, Journal of Clinical Oncology and Bone Marrow Transplantation, as well as numerous abstracts of papers at national and international meetings.

Tuesday, May 5th
5pm–6pm PST
RSVP NOW

Matthew Davids, MD, MMSc
Assistant Professor, Medicine, Harvard Medical School
Attending Physician, Lymphoma Group, Medical Oncology—Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Associate Director of the Dana-Farber CLL Center

After obtaining an A.B. in chemistry at Harvard College, Dr. Davids completed his M.D. at Yale University School of Medicine. He served as an intern, resident, and assistant chief resident in internal medicine at New York-Presbyterian Weill Cornell Medical Center and Memorial Sloan-Kettering Cancer Center in New York City. He then completed his fellowship in hematology and oncology in Dana-Farber/Partners CancerCare, and a Masters in Medical Science (MMSc) at Harvard Medical School. Dr. Davids has an active translational research program in chronic lymphocytic leukemia (CLL), studying Bcl-2 biology in his laboratory and leading clinical trials to evaluate a variety of novel therapeutic strategies in patients with CLL and other hematologic malignancies.

Wednesday, May 6th
5pm–6pm EST
RSVP NOW

Additional programs available on MRD in acute lymphoblastic leukemia (ALL) and multiple myeloma.
Programs on MRD in chronic myeloid leukemia (CML) and acute myeloid leukemia (AML) forthcoming.